Thromb Haemost 2001; 86(05): 1314-1319
DOI: 10.1055/s-0037-1616070
Scientific and Standardization Committee Communications
Schattauer GmbH

Production of Tissue Factor Pathway Inhibitor in Cardiomyocytes and Its Upregulation by Interleukin-1

Anne Kereveur
1   Department of Etiology and Pathogenesis, Research Institute, Suita, Osaka, Japan
,
Keiichi Enjyoji
1   Department of Etiology and Pathogenesis, Research Institute, Suita, Osaka, Japan
,
Kazuyoshi Masuda
2   Department of Pathology, National Cardiovascular Center, Suita, Osaka, Japan
,
Chikao Yutani
2   Department of Pathology, National Cardiovascular Center, Suita, Osaka, Japan
,
Hisao Kato
1   Department of Etiology and Pathogenesis, Research Institute, Suita, Osaka, Japan
› Author Affiliations
Further Information

Publication History

Received 04 June 2001

Accepted 04 June 2001

Publication Date:
13 December 2017 (online)

 

 
  • References

  • 1 Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 73: 873-5.
  • 2 Flossel C, Luther T, Muller M, Albrecht S, Kasper M. Immunohisto-chemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue. Histochemistry 1994; 101: 449-53.
  • 3 Schonbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR, Libby P. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000; 156: 7-14.
  • 4 Zhou L, Stordeur P, de Lavareille A, Thielemans K, Capel P, Goldman M, Pradier O. CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost 1998; 79: 1025-8.
  • 5 Schnitt SJ, Stillman IE, Owings DV, Kishimoto C, Dvorak HF, Abelmann WH. Myocardial fibrin deposition in experimental viral myocarditis that progresses to dilated cardiomyopathy. Circ Res 1993; 72: 914-20.
  • 6 Erlich JH, Boyle EM, Labriola J, Kovacich JC, Santucci RA, Fearns C, Morgan EN, Yun W, Luther T, Kojikawa O, Martin TR, Pohlman TH, Verrier ED, Mackman N. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000; 157: 1849-62.
  • 7 Takada H, Kishimoto C, Hiraoka Y, Kurokawa M, Shiraki K, Sasayama S. Captopril suppresses interstitial fibrin deposition in coxsackievirus B3 myocarditis. Am J Physiol 1997; 272: H211-9.
  • 8 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
  • 9 Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein- associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A 1990; 87: 8869-73.
  • 10 Idell S, Pendurthi U, Pueblitz S, Koenig K, Williams T, Rao LV. Tissue factor pathway inhibitor in tetracycline-induced pleuritis in rabbits. Thromb Haemost 1998; 79: 649-55.
  • 11 Cella G, Cipriani A, Tommasini A, Rampin E, Sbarai A, Rocconi R, Mazzaro G, Luzzatto G. Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration. Semin Thromb Hemost 1997; 23: 45-9.
  • 12 Bajaj MS, Steer S, Kuppuswamy MN, Kisiel W, Bajaj SP. Synthesis and expression of tissue factor pathway inhibitor by serum- stimulated fibroblasts, vascular smooth muscle cells and cardiac myocytes. Thromb Haemost 1999; 82: 1663-72.
  • 13 Huang ZF, Higuchi D, Lasky N, Broze Jr GJ. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 944-51.
  • 14 Kaiser B, Fareed J. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb Haemost 1996; 76: 615-20.
  • 15 Rapp JH, Pan XM, Ghermay A, Gazetas P, Brady SE, Reilly LM. A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model. J Vasc Surg 1997; 25: 726-9.
  • 16 Creasey AA, Chang AC, Feigen L, Wun TC, Taylor Jr FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-6.
  • 17 Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-50.
  • 18 Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997; 96: 646-52.
  • 19 Zoldhelyi P, McNatt J, Shelat HS, Yamamoto Y, Chen ZQ, Willerson JT. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 2000; 101: 289-95.
  • 20 Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992; 79: 3219-26.
  • 21 van der Logt CP, Dirven RJ, Reitsma PH, Bertina RM. Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester. Blood Coagul Fibrinolysis 1994; 5: 211-20.
  • 22 Caplice NM, Mueske CS, Kleppe LS, Peterson TE, Broze Jr GJ, Simari RD. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res 1998; 83: 1264-70.
  • 23 Fleck RA, Rao LV, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody [corrected and republished article originally printed in Thromb Res 1990 Mar 1;57(5):765-81]. Thromb Res 1990; 59: 421-37.
  • 24 Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998; 79: 495-9.
  • 25 Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 1995; 96: 1280-7.
  • 26 Annex BH, Denning SM, Channon KM, Sketch Jr MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-22.
  • 27 Holschermann H, Bohle RM, Zeller H, Schmidt H, Stahl U, Fink L, Grimm H, Tillmanns H, Haberbosch W. In situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy. Am J Pathol 1999; 154: 211-20.
  • 28 Caplice NM, Mueske CS, Kleppe LS, Simari RD. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998; 98: 1051-7.
  • 29 Labarrere CA, Pitts D, Halbrook H, Faulk WP. Natural anticoagulant pathways in normal and transplanted human hearts. J Heart Lung Transplant 1992; 11: 342-7.
  • 30 Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, Tanigawa M, Nishikawa H, Yamada N, Isaka N, Nakano T, Kumeda K, Kato H. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997; 55: 183-7.
  • 31 Saito Y, Wada H, Yamamuro M, Inoue A, Shimura M, Hiyoyama K, Gabazza EC, Isaka N, Shiku H, Takeya H, Suzuki K, Kumeda K, Kato H, Nakano T. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am J Hematol 1999; 61: 238-42.
  • 32 O’Neill LA, Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol 1998; 63: 650-7.
  • 33 Bowie A, O’Neill LA. The interleukin-1 receptor/Toll-like receptor super-family: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 2000; 67: 508-14.
  • 34 Tamaru M, Tomura K, Sakamoto S, Tezuka K, Tamatani T, Narumi S. Interleukin-1beta induces tissue- and cell type-specific expression of adhesion molecules in vivo. Arterioscler Thromb Vasc Biol 1998; 18: 1292-303.
  • 35 Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction [published erratum appears in Proc Natl Acad Sci USA 1990 Apr; 87 (7):2 865]. Proc Natl Acad Sci USA 1989; 86: 9717-21.
  • 36 Enjyoji K, Emi M, Mukai T, Kato H. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem (Tokyo) 1992; 111: 681-7.
  • 37 Girard TJ, Warren LA, Novotny WF, Bejcek BE, Miletich JP, Broze Jr GJ. Identification of the 1.4 kb and 4.0 kb messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein. Thromb Res 1989; 55: 37-50.
  • 38 Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998; 98: 149-56.
  • 39 Tofukuji M, Metais C, Li J, Franklin A, Simons M, Sellke FW. Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. Circulation 1998; 98: II242-6 discussion II247-8.
  • 40 Shimokawa T, Yamamoto K, Kojima T, Saito H. Down-regulation of murine tissue factor pathway inhibitor mRNA by endotoxin and tumor necrosis factor-alpha In vitro and In vivo. Thromb Res 2000; 100: 211-21.
  • 41 Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2394-400.
  • 42 Arend WP. Interleukin-1 receptor antagonist: discovery, structure and properties. Prog Growth Factor Res 1990; 2: 193-205.
  • 43 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97.
  • 44 Kamikubo Y, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett 1997; 407: 116-20.
  • 45 Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Kamikubo Y, Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Haemost 1997; 78: 1138-41.
  • 46 Labarrere CA, Nelson DR, Faulk WP. Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med 1998; 105: 207-13.
  • 47 Hamuro T, Kamikubo Y, Nakahara Y, Miyamoto S, Funatsu A. Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett 1998; 421: 197-202.
  • 48 Takemura G, Ohno M, Hayakawa Y, Misao J, Kanoh M, Ohno A, Uno Y, Minatoguchi S, Fujiwara T, Fujiwara H. Role of apoptosis in the disappearance of infiltrated and proliferated interstitial cells after myocardial infarction. Circ Res 1998; 82: 1130-8.